# Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain

> **NCT00576277** · PHASE1,PHASE2 · COMPLETED · sponsor: **Avigen** · enrollment: 36 (estimated)

## Conditions studied

- Diabetic Neuropathy

## Interventions

- **DRUG:** AV411

## Key facts

- **NCT ID:** NCT00576277
- **Lead sponsor:** Avigen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2007-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576277, "Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00576277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*